Autumn marks one of the busiest and most inspiring times of the year for the pharma and drug delivery community. With major industry events such as the PDA in Vienna and the CPHI in Frankfurt taking place across Europe, it is the perfect time to connect with partners, exchange ideas, and explore innovations that are shaping the future of self-injection. Here we take a closer look at our experiences at these conferences and give you the inside track on what made them stand out this season.
PDA Vienna – The hub for combination product expertise
Held on October 21–22 at the Austria Center Vienna, the PDA Universe of Pre-Filled Syringes & Injection Devices Conference brought together experts from across the injectable combination product ecosystem. This year’s theme, Shaping the Drug Delivery Ecosystem, highlighted how advances in science, technology, and sustainability are redefining injectable therapies.
Unlike broader industry events, PDA offers a highly focused forum dedicated to pre-filled syringes and injection devices, making it a key meeting point for technical specialists and innovators. From early morning keynotes to impromptu discussions at the Ypsomed booth, the event offered countless opportunities to share experiences and expertise. Ypsomed was well represented, with Jakob Lange, VP & Head of Account and Business Development, serving as conference co-chair and helping to guide discussions on emerging challenges and opportunities in drug delivery.
The event also marked the official reveal of our new YpsoLoop autoinjector, which generated significant buzz among attendees. Visitors to the Ypsomed booth were eager to learn about just how this award-winning device unites sustainability and patient convenience – both critical to the next generation of self-injection devices. At our Innovation Hub, attendees also got a first look at YpsoDot, the pre-filled, cartridge-based pull-push pen designed for multiple injections of a fixed dose up to 1 mL. The pen is designed to support the growing needs in obesity management and related therapies.
CPHI Frankfurt – The global stage for pharma innovation
CPHI Frankfurt (October 28–30 at Messe Frankfurt) is widely recognized as the largest pharmaceutical industry gathering in the world. This three-day event draws more than 63,000 professionals from 160+ countries, alongside over 2,000 exhibitors and six dedicated content theatres spanning everything from APIs and finished-dosage manufacturing to bioproduction, CDMOs, packaging and drug delivery. What really sets CPHI apart is its scale and breadth, bringing together the full supply chain – suppliers, manufacturers, service providers, regulators, innovators, and beyond, all under one roof.
At Ypsomed’s booth this year, the energy was palpable. The halls of Messe Frankfurt were buzzing from morning to evening, with back-to-back meetings, product demos, and spontaneous exchanges filling every corner. Amid the constant movement and conversation, our team had the chance to connect with long-standing partners and new faces alike, all eager to discuss what’s next in drug delivery. Two highlights at our booth drew particular attention: the UnoPen preconfigured for GLP-1, designed for semaglutide therapies and supporting fast time-to-market through its pretested and prefilled setup; and the YpsoFlow spring-driven prefilled pen, combining trusted usability, bio-based materials, and a smooth path to market.
Beyond these device highlights, Ypsomed’s success was further underscored when the YpsoLoop autoinjector secured a top honor at the CPHI Pharma Awards in the Drug Delivery and Device Innovation category – a powerful affirmation of our commitment to sustainable and patient-centric design on the global stage.
Bringing it all together
With these two conferences behind us, we return inspired by the momentum in our industry and the opportunities ahead. Across both events, one theme stood out clearly: the growing convergence of patient-centric design, sustainability, and technological innovation. From specialist discussions in Vienna to global conversations in Frankfurt, it is evident that the next chapter in drug delivery will depend on collaboration and the ability to translate these priorities into real-world solutions.
Learn more about what we do here.
